Detalhe da pesquisa
1.
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med
; 388(21): 1966-1980, 2023 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37224198
2.
Deep historical borrowing framework to prospectively and simultaneously synthesize control information in confirmatory clinical trials with multiple endpoints.
J Biopharm Stat
; 32(1): 90-106, 2022 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34632951
3.
A practical response adaptive block randomization (RABR) design with analytic type I error protection.
Stat Med
; 40(23): 4947-4960, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34111902
4.
Identification of Extracellular Key Enzyme and Intracellular Metabolic Pathway in Alginate-Degrading Consortia via an Integrated Metaproteomic/Metagenomic Analysis.
Environ Sci Technol
; 55(24): 16636-16645, 2021 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34860015
5.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Lancet
; 392(10148): 650-661, 2018 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30097359
6.
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
J Am Acad Dermatol
; 78(1): 90-99.e1, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28993005
7.
Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.
Acta Derm Venereol
; 98(10): 932-937, 2018 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30085324
8.
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial.
Dermatol Ther (Heidelb)
; 13(5): 1099-1111, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892753
9.
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
J Dermatolog Treat
; 33(4): 2085-2093, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33947295
10.
Elucidating the production and inhibition of melanoidins products on anaerobic digestion after thermal-alkaline pretreatment.
J Hazard Mater
; 424(Pt A): 127377, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34879570
11.
Controlling volatile fatty acids production from waste activated sludge by an alginate-degrading consortium.
Sci Total Environ
; 806(Pt 3): 150730, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34606857
12.
Decoupling mechanism of Acid Orange 7 decolorization and sulfate reduction by a Caldanaerobacter dominated extreme-thermophilic consortium.
J Hazard Mater
; 419: 126498, 2021 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34214849
13.
An automation-based adaptive seamless design for dose selection and confirmation with improved power and efficiency.
Stat Methods Med Res
; 30(4): 1013-1025, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33459183
14.
Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
JAMA Surg
; 156(11): 1001-1009, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34406349
15.
Caproate production from xylose by mesophilic mixed culture fermentation.
Bioresour Technol
; 308: 123318, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32278998
16.
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
JAMA Dermatol
; 156(12): 1344-1353, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33052382
17.
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
JAMA Dermatol
; 156(6): 649-658, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32267471
18.
Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies.
Wounds
; 29(11): E98-E102, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29166256